Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.40 |
| ▸ | LSS | P48449 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ALOX15B | O15296 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL482279 | 0.94 | HTR3A (0.48) | HTR3ADRD2ADRA1ASLC18A3LSS | |
| SCHEMBL5544343 | 0.86 | HTR3A (0.47) | HTR3ADRD2ADRA1ASLC18A3LSS | |
| SCHEMBL18533598 | 0.85 | HTR3A (0.52) | HTR3ADRD2ADRA1ASLC18A3LSS | |
| SCHEMBL1366932 | 0.82 | HTR3A (0.46) | HTR3ADRD2ADRA1ASLC18A3LSS | |
| SCHEMBL19090025 | 0.79 | HTR3A (0.52) | HTR3ADRD2SLC18A3CYP1A2KMT2A | |
| SCHEMBL315186 | 0.78 | HTR3A (0.58) | HTR3ADRD2SLC18A3LSSCYP1A2 | |
| SCHEMBL218475 | 0.73 | HTR3A (0.59) | HTR3ADRD2SLC18A3LSSCYP1A2 | |
| SCHEMBL435619 | 0.73 | HTR3A (0.59) | HTR3ADRD2SLC18A3LSSSRD5A1 | |
| SCHEMBL8021843 | 0.73 | ESR2 (0.44) | HTR3ADRD2SLC18A3LSSCYP1A2 | |
| SCHEMBL8021842 | 0.73 | ESR2 (0.44) | HTR3ADRD2SLC18A3LSSCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | claimed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | claimed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | claimed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | claimed |
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | BRITISH BIOTECH PHARMACEUTICALS LTD. (GB) | 2003-03-13 | — | — | US | disclosed |
| US-6479502-B1 | TREATMENT OF DISEASES AND CONDITIONS RESPONSIVE TO MODULATION OF MATRIX METALLOPROTEINASE ACTIVITY | BRITISH BIOTECH PHARMACEUTICALS (GB) | 2002-11-12 | — | — | US | disclosed |
| EP-1107953-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-06-20 | — | — | EP | disclosed |
| WO-2000012477-A1 | HYDROXAMIC ACID DERIVATIVES AS PROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050310-A1 | Hydroxamic acid derivatives as proteinase inhibitors | MMP2, CTSH, TIMP3 | HTR3A 1377/4885DRD2 4698/4885ADRA1A 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.